OMEICOS Therapeutics Completes Enrollment of PMD-OPTION Study in Primary Mitochondrial Disease
26. September 2024 06:00 ET
|
OMEICOS Therapeutics GmbH
Interim data confirms OMT-28’s strong safety profile in PMD patients, top-line data expected mid-2025 BERLIN, GERMANY, September 26, 2024 – OMEICOS, a biopharmaceutical company developing...
ImmuneSensor Therapeutics Receives Clearance from Australian Regulators to Initiate a First-in-Human Phase 1 Clinical Trial of cGAS inhibitor Drug Candidate, IMSB301
19. August 2024 08:00 ET
|
ImmuneSensor Therapeutics
Novel, oral IMSB301 is a potent cGAS inhibitor designed to block signaling through a central pathway that drives diverse inflammatory and autoimmune diseases Company expects to initiate its Phase 1...
Ashwagandha Market is Likely to Reach USD 1.9 billion by 2034 at a CAGR of 9.2% | Report Analysis by Transparency Market Research Inc.
12. August 2024 05:24 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. -, Aug. 12, 2024 (GLOBE NEWSWIRE) -- The global ashwagandha market (아슈와간다 시장) was projected to attain US$ 692.9 million in...
Snif-Snax Wins “Natural Dog Treat Product of the Year” In 2024 Pet Innovation Awards
06. August 2024 08:00 ET
|
Pet Innovation Awards
LOS ANGELES, Aug. 06, 2024 (GLOBE NEWSWIRE) -- The 2024 Pet Innovation Awards, an independent recognition platform highlighting the most innovative companies, services, and products in the highly...
Derm-Biome Pharmaceuticals and TransBIOtech awarded $450,000 Applied Research and Development (ARD) grant funding
08. Mai 2024 10:00 ET
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based biopharmaceutical company focused on skin health and healthy aging, is pleased to...
Derm-Biome Pharmaceuticals prepares to begin IND-enabling studies for DB-007-4, a potential best-in-class treatment for inflammatory skin diseases
27. Februar 2024 10:00 ET
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals Inc, a Vancouver-based biopharmaceutical company developing novel topical therapies for inflammatory skin...
Basil Extracts Market to exceed $1.5 Bn by 2032, Says Global Market Insights Inc.
17. Januar 2024 20:30 ET
|
Global Market Insights Inc.
Selbyville, Delaware, Jan. 17, 2024 (GLOBE NEWSWIRE) -- The basil extracts market valuation is anticipated to reach USD 1.5 billion by 2032, as reported in a research study by Global Market...
Animal Drug Compounding Market is Predicted to Reach USD 2.4 billion by 2031, Registering a 7.4% CAGR: TMR Report
04. Oktober 2023 03:47 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The animal drug compounding market acquired US$ 1.1 billion in 2021. The market is likely...
Incannex Company Presentation – Results from Phase 1 Clinical Trial to Assess Proprietary IHL-675A
03. Mai 2023 07:30 ET
|
Incannex Healthcare
MELBOURNE, Australia, May 03, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or ‘the Company’) is pleased to announce a company presentation containing data...
Bruder Healthcare Now Exclusive Licensor of the Dry Eye Drink™ -- First and Only Ophthalmic Anti-Inflammatory Hyper-Hydrating Drink
13. Februar 2023 10:00 ET
|
Bruder Healthcare
ATLANTA, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Bruder Healthcare, a Hilco Vision Company, announced an exclusive licensing agreement with Baton Rouge-based Dry Eye Drink LLC, the manufacturer of a...